NCT07439328Completed
ASTRA Study: Circulating Tumor Cells in Blood of Patients With High-Grade Serous Ovarian Cancer
ASTRA: Circulating Tumor Cells in Blood of Patients With High-Grade Serous Ovarian Cancer-Morphology, Immunophenotype, and Association With Clinical Outcomes
Source: ClinicalTrials.gov · Last updated 27 Feb 2026
Brief summary (registry, in English)
High-grade serous ovarian cancer is typically diagnosed at an advanced stage and remains associated with poor long-term survival. Reliable biomarkers for predicting disease course and treatment response are still limited. Circulating tumor cells (CTCs) are malignant cells that detach from the primary tumor and enter the bloodstream. Their presence has been associated with disease progression and prognosis in several malignancies, including ovarian cancer. However, data on the morphological characteristics, immunophenotype, and clinical relevance of CTCs in high-grade serous ovarian cancer remain limited. The ASTRA study evaluates the number and characteristics of circulating tumor cells in peripheral blood samples obtained from patients with high-grade serous ovarian cancer. The study examines CTC count, presence of CTC clusters and megakaryocytes, and immunophenotypic marker expression, and explores associations between CTC findings and clinical parameters and outcomes. Results from this study may contribute to improved understanding of circulating tumor cells in ovarian cancer and support the development of liquid biopsy approaches for prognostic assessment and disease monitoring.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 30 (actual)
- First submitted
- 4 Feb 2026
- Start date
- 1 Jan 2024
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Institute of Oncology Ljubljana
- Diseases
- Ovarian cancer
- NCT number
- NCT07439328
What you commit to
- Study type: Interventional
- Participants enrolled: 30
- From 1 Jan 2024 to the primary completion date, 31 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Presence of another active malignancy.
- Any condition that, in the opinion of the investigators, could interfere with study participation or interpretation of results.
Who the study is looking for
- Female patients aged 18 years or older.
- Histologically confirmed high-grade serous ovarian cancer.
- FIGO stage III or IV disease.
- Indication for first-line platinum-based systemic therapy.
- ECOG/WHO performance status 0-2.
- Ability to provide peripheral blood samples.
- Written informed consent obtained prior to participation.
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institute of Oncology Ljubljana Coordinator of this site? Confirm its status | Ljubljana | Slovenia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.